Sun C S, Wilson S Z, Wyde P R
Proc Soc Exp Biol Med. 1986 Feb;181(2):298-304. doi: 10.3181/00379727-181-42257.
Hybrid recombinant human alpha interferon A/D (rIFN A/D) is unusual in that it has equivalent antiviral activity in in vitro assays using mouse or human tissue cells. This interferon was delivered to outbred Swiss mice in small particle aerosols before and/or after these mice were inoculated with virulent influenza A/HK/68 virus. Although rIFN A/D was effective in inhibiting influenza virus replication in vitro in primary mouse embryo cells, it had only a limited degree of effectiveness in the in vivo tests; only animals exposed to rIFN A/D for 4 hr and inoculated with influenza virus 4 hr later exhibited a significant decrease in mortality (approximately 25% reduction in deaths; P less than 0.025) compared with that of the untreated control animals. The limited effectiveness of rIFN A/D seen in these studies indicated that the use of this or similar recombinant alpha interferons alone to prevent or treat influenza virus infection in humans is not promising.
杂合重组人α干扰素A/D（rIFN A/D）不同寻常之处在于，在使用小鼠或人体组织细胞进行的体外试验中，它具有同等的抗病毒活性。在远交系瑞士小鼠接种强毒A/HK/68流感病毒之前和/或之后，以小颗粒气雾剂形式将这种干扰素递送至小鼠体内。尽管rIFN A/D在体外对原代小鼠胚胎细胞中的流感病毒复制具有抑制作用，但在体内试验中其有效性有限；与未治疗的对照动物相比，仅在接触rIFN A/D 4小时后再接种流感病毒的动物死亡率显著降低（死亡减少约25%；P<0.025）。这些研究中观察到的rIFN A/D有效性有限表明，单独使用这种或类似的重组α干扰素预防或治疗人类流感病毒感染前景不佳。
